Aim: To determine whether a 5-day regimen with rabeprazole, clarithromycin and amoxicillin (RCA) was as effective as a 7-day regimen.
Methods: A total of 139 H. pylori-infected patients were randomized to receive either a 5-day or 7-day course of rabeprazole 10 mg b.d., clarithromycin 400 mg b.d. and amoxicillin 750 mg b.d. Eradication was assessed by CLO test, histology and 13C-urea breath test.
Results: On the intention-to-treat basis, eradication rates were 66% (46 out of 70) and 84% (58 out of 69) for the 5- and 7-day regimens, respectively (P < 0.05). Using per protocol analysis, eradication rates were 70% (46 out of 66) and 91% (58 out of 64) for the 5- and 7-day regimens, respectively (P < 0.01). Adverse events, which were observed in 14 patients from each group, caused discontinuation of treatment in only two patients, resulting in excellent compliance.
Conclusions: Our 5-day regimen of RCA yielded inferior results, whereas the 7-day regimen achieved an eradication rate exceeding 90% on the per protocol basis. Therefore, treatment regimens of less than 7 days for proton pump inhibitor-clarithromycin-amoxicillin therapies cannot be recommended.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1365-2036.2000.00892.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of tegoprazan- and rabeprazole-based concomitant therapies for Helicobacter pylori infection: Real-world evidence.
J Gastroenterol Hepatol
November 2024
Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Article Synopsis
- Tegoprazan, a new acid blocker, was compared to rabeprazole in treating Helicobacter pylori infections, with a focus on effectiveness in real-world settings.
- An analysis of 1,474 patients showed similar eradication rates for both medications, with tegoprazan at 74.7% and rabeprazole at 72.7%, indicating no significant difference.
- Although there were no major differences in overall adverse events, tegoprazan resulted in fewer cases of abdominal discomfort compared to rabeprazole, prompting suggestions for further research on its application in different treatment regimens.
Comparison of Helicobacter pylori eradication rates between 7 and 14 days of tailored therapy according to clarithromycin resistance test: A randomized, multicenter, non-inferiority study.
Helicobacter
May 2024
Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Republic of Korea.
Article Synopsis
- A recent study compared the effectiveness of 7-day versus 14-day tailored therapies for eradicating Helicobacter pylori (H. pylori), specifically focusing on patients with clarithromycin resistance.
- The study involved H. pylori-positive patients who were randomly assigned to either regimen and evaluated for eradication rates and adverse events.
- Results showed similar eradication rates between the two groups, confirming that the shorter 7-day treatment is as effective as the 14-day regimen, with no significant differences in side effects.
Amoxicillin, gemifloxacin and rabeprazole, as first-line Helicobacter pylori therapy in clinical practice: A pilot study.
Medicine (Baltimore)
May 2024
Van Training and Research Hospital, Department of Internal Medicine, Division of Gastroenterology, Van, Turkey.
Success in eradication of H. pylori is decreasing due to increasing resistant strains. In particular, side-effects due to 4-agent treatment multiple drug use are observed and treatment compliance decreases.
View Article and Find Full Text PDFRole of MIC levels and 23S rRNA mutation sites to clarithromycin in 14-day clarithromycin bismuth quadruple therapy for eradication: A prospective trial in Beijing.
Heliyon
April 2024
Department of Gastroenterology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, China.
Background: Rising clarithromycin resistance undermines () treatment efficacy. We aimed to determine clarithromycin's minimum inhibitory concentration (MIC) levels and identify specific mutation sites in the 23S ribosomal subunit (23S rRNA) that predict treatment outcomes in a 14-day regimen of clarithromycin bismuth quadruple therapy (amoxicillin 1g, clarithromycin 500 mg, rabeprazole 10 mg, and colloidal bismuth pectin 200 mg).
Materials And Methods: We included adult patients who hadn't previously undergone clarithromycin-based treatment, either as initial or rescue therapy.
Optimized sequential therapy 10- and 14-d concomitant therapy for eradicating : A randomized clinical trial.
World J Gastroenterol
February 2024
Department of Gastroenterology II, Mohammed V Military Teaching Hospital of Rabat, Rabat 10100, Morocco.
Background: A cure for () remains a problem of global concern. The prevalence of antimicrobial resistance is widely rising and becoming a challenging issue worldwide. Optimizing sequential therapy seems to be one of the most attractive strategies in terms of efficacy, tolerability and cost.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!